Stock Trading Ideas

JP Morgan Cautions Trade Tensions Are Weighing On Eastman Chemical Growth Prospects

GM Q1 Earnings On Tap: 2025 Could Be The Year 'Margins Surprise'

Coca-Cola Q1 Earnings Preview: Will Warren Buffett Favorite Continue To Be A 'Safe Haven' Stock?

GM Q1 Earnings On Tap: 2025 Could Be The Year 'Margins Surprise'

Coca-Cola Q1 Earnings Preview: Will Warren Buffett Favorite Continue To Be A 'Safe Haven' Stock?

Stock Of The Day: Will Microsoft Take The Entire Market Higher?

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

Stock Of The Day: Will Microsoft Take The Entire Market Higher?

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

Coke Vs. Coffee: Can Coca-Cola Stay Fizzy? Starbucks' Rebound After Earnings?

Trading Ideas Recent News

Ambiguous Signals In Economic Data

The soft, sentiment-oriented data has been disappointing, while hard data, which reflects actual economic activity, has been strong.

How You'll Know When Tariff Troubles Are Finally Over

Markets Face Crucial Week Ahead...

This week brings a packed schedule of earnings announcements, economic reports, and headline news, ushering in new market catalysts.

Barclays Flags Macy's, Kohl's Risks During Consumer Weakness; Highlights Gildan, Levi's For Strength

Barclays analyst Paul Kearney initiated coverage on Gildan Activewear, Macy's, Columbia Sportswear, Carter's and Kohl's, with mixed ratings and price forecasts. Despite strong U.S. consumer trends, Kearney remains cautious, citing market volatility and tariff risks impacting apparel sales into 2026.

UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates

UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for UGN-301 in bladder cancer.

Charter's Strong Network, New Bundles Drive Analyst Optimism For Long-Term Growth

Oppenheimer analyst Timothy Horan rates Charter Communications Inc. as Perform.

These Analysts Revise Their Forecasts On Celestica After Q1 Earnings

Why Is Summit Therapeutics Stock Trading Higher On Monday?

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial.

Colgate-Palmolive Analysts Increase Their Forecasts After Upbeat Results

These Analysts Cut Their Forecasts On Aon After Weak Earnings

Saia Analysts Slash Their Forecasts After Downbeat Results

China Risk To Nvidia, Flood Of Earnings And Jobs Report Ahead

To gain an edge, this is what you need to know today.

Apple Q2 Will Be 'Better-Than-Feared': Analyst Says iPhone Company Has 'Proven Track Record'

An Apple analyst sees the stock reporting better-than-expected Q2 results this week and having a strong fiscal year.

Navigating A Roller Coaster Market

Trading the chaos--profitably.

CVR Energy Q1 Earnings On Deck: Carl Icahn Loads Up While Wall Street Waits